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Abstract 
Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb) 
localize within a tumor by virtue of its anti-tumor binding site(s) before administering a small, 
fast-clearing radiolabeled compound that then attaches to the other portion of the bsMAb. 
The compound’s rapid clearance significantly reduces radiation exposure outside of the tumor 
and its small size permits speedy delivery to the tumor, creating excellent tumor/nontumor 
ratios in less than 1 hour. Haptens that bind to an anti-hapten antibody, biotin that binds to 
streptavidin, or an oligonucleotide binding to a complementary oligonucleotide sequence have 
all been radiolabeled for use by pretargeting. This review will focus on a highly flexible an-
ti-hapten bsMAb platform that has been used to target a variety of radionuclides to image 
(SPECT and PET) as well as treat tumors. 
Key words: bispecific antibody, cancer detection, pretargeting, radioimmunodetection, radioim-
munotherapy. 
Introduction 
The exquisite specificity afforded by antibodies 
has long been recognized for their ability to serve as 
carriers of other substances. Studies in the 1950’s were 
the first to show that radiolabeled antibodies directed 
against  tissue  antigens  could  specifically  localize  in 
these tissues, and shortly thereafter, selective tumor 
targeting was demonstrated [1, 2]. It was not until the 
early  1970’s  that  suitable  human  tumor-associated 
antigens were identified that could be used for tar-
geting radionuclides for tumor visualization and later 
for therapy [3-5]. Thus, radiolabeled antibodies were 
the first “theranostic” agents, capable of both detec-
tion and therapy.  
 Antibodies do not have any selective ability to 
home to tumors, but need to come into contact with 
cancer cells after being distributed through the fluid 
highways  of  the  body,  the  blood  and  lymphatic 
channels, to enter the tumor’s vascular supply. The 
imperfect vascular supply of a tumor creates an en-
vironment  that  is  more  permissive  for  macromole-
cules  to  enter  their  extravascular  space  than  most 
normal  tissues  [6-9].  Thus,  even  a  non-specific  IgG 
and other macromolecules have an increased accre-
tion in tumor compared to most normal tissues [10, 
11].  Because  tumors  lack  lymphatic  drainage,  back-
pressure inside builds, creating a physiological barrier 
that  impedes  a  macromolecule’s  diffusion  into  the 
tumor; however, smaller molecules permeate better. 
As the antibody  molecules leave the blood and en-
counters antigen on tumor cells in the extravascular 
compartment,  they  will  be  retained  for  variable 
lengths of time, dictated mainly by their affinity and 
valency (avidity), while the remaining antibody mol-
ecules in the body eventually clear by normal physi-
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ological  mechanisms  that  remove  proteins  and  for-
eign  substances  [12].  The  selective  binding  actually 
impedes the antibody from migrating too far from the 
perivascular space where it first encounters the anti-
gen, with antibodies that have a lower binding affinity 
being released more quickly and better able to con-
tinue  penetrating  deeper  into  the  tumor  than  those 
with a higher affinity [13].  
 Since antibodies are designed to be retained in 
the  serum,  their  re-circulation  aids  in  building  the 
concentration in the tumor to a maximum level over 
1-2  days.  However,  even  with  delayed  blood  clear-
ance, only a very small fraction of the injected dose 
will localize to the tumor. The slow blood clearance 
maintains background activity at high levels, and thus 
tumor  discrimination  can  require  several  days.  Re-
ducing the molecular size or removing/altering the 
neonatal  receptor-binding  site,  which  is  responsible 
for sustained IgG levels in the blood (by enzymatic 
digestion  or  molecular  engineering),  can  accelerate 
blood clearance, but this reduces re-circulation, lead-
ing to decreased tumor accretion [14-18]. Because op-
timal targeting is a combination of high specific up-
take  and  low  retention  in  normal  tissues,  often  the 
gains made in hastening clearance are offset by lower 
tumor uptake, and thus the net effect can be modest. 
This is particularly problematic for an agent that is 
intended for both imaging and therapy, where certain 
modifications that might improve imaging properties 
can  compromise  or  place  certain  restrictions  on  the 
therapeutic  application.  For  example,  molecular  en-
gineering  has  created  a  wide  variety  of  antibody 
forms with different valencies and molecular sizes. At 
a  molecular  size  of  ~25  kD,  the  smallest  antibody 
fragment from an IgG, a scFv, has monovalent bind-
ing and clears exceptionally fast from the blood and 
tissues, creating much higher tumor/nontumor ratios 
much more quickly than an IgG (160 kD). This anti-
body form, and its divalent variant, a diabody, could 
be used for imaging, but tumor uptake and retention 
is  reduced  so  significantly  for  both  that  they  have 
virtually no therapeutic value as directly-labeled ra-
dioconjugates, at least for systemic applications. Oth-
er  larger  divalent  forms,  such  as  minibodies  and 
(scFv)2-Fc  constructs,  have  somewhat  slower  blood 
clearance  with  higher  tumor  retention,  enhancing 
their use for imaging, but studies have suggested their 
therapeutic application would likely be restricted to 
radioiodinated forms [16, 19-21]. 
 Indeed, one of the major issues facing investi-
gators seeking radioconjugates for therapeutic use is 
isotope  selection,  which  is  often  dictated  by  the 
pharmacokinetics  and  biodistribution  of  the  direct-
ly-radiolabeled  antibody.  Radioiodine  is  commonly 
coupled to an antibody’s tyrosine residues, and when 
catabolized,  iodotyrosine  is  released  from  the  cells, 
which  is  quickly  and  efficiently  removed  from  the 
body with some retention by the thyroid [22-26]. 123I, 
131I,  125I,  and  124I  all  have  been  used  for  imaging 
and/or therapy, and since they can all be coupled to 
antibodies  with  the  same  procedure,  radioiodine  is 
often an attractive radionuclide for theranostic appli-
cations. Nevertheless, there are many more radionu-
clides of interest for imaging and therapy, particularly 
radiometals.  
 Radiometals  are  usually  coupled  to  antibodies 
through an intermediate, a chelating agent. Chelating 
agents often have differing affinities for various met-
als, and thus  the  in vivo stability of  one radiometal 
bound  to  a  particular  antibody-chelate  conjugate 
might not be the same as another radiometal bound to 
the same conjugate. Radiometals that are brought into 
cells  by  an  antibody  are  retained  for  long  periods, 
because cells tend to retain metals, but metals held by 
chelates also are inhibited from being expelled [27-29]. 
Thus, radiometal-labeled antibodies will have signif-
icantly higher uptake in the liver and kidneys for IgG 
or smaller fragments, respectively. This retention also 
will occur in the tumor, with radiometal-labeled an-
tibody accretion in tumor gradually increasing over 
time, reflecting the cumulative deposition of the ra-
diometal in the cells, particularly for antibodies that 
readily  internalize.  Although  radiometals  become 
trapped in the liver, elevated uptake in the liver has 
not  been  problematic  for  directly-radiolabeled  IgG, 
since  dose-limiting  hematologic  toxicity  occurs  well 
before  radiation  doses  to  the  liver  approach  critical 
levels. When using smaller antibody fragments that 
clear through the kidneys in an attempt to reduce red 
marrow exposure, renal uptake then can far exceed 
that  of  the  tumor.  Since  kidneys  have  an  upper 
threshold  of  tolerance  of  perhaps  ~2500  cGy,  while 
solid tumors may be eradicated by external beam ir-
radiation with ~5000 cGy [30], it is difficult to envision 
a successful radiotherapeutic when renal exposure is 
so much higher than tumor. One way to circumvent 
these  problems  has  been  to  explore  compartmental 
treatment strategies, such as direct injection into sur-
gical cavities in the cerebrum for brain cancers or the 
peritoneum  for  carcinomatosis  [31].  In  these  exam-
ples, a larger fraction of the injected product will re-
main  in  the  local  compartment,  which  reduces  the 
potential exposure of other tissues. 
 Thus,  for  optimal  targeting,  systemical-
ly-administered,  directly-radiolabeled  antibodies 
might need to use 2 different forms, e.g., a fragment 
for imaging and an IgG for therapy. However, imag-
ing is rarely performed solely for the purpose of con-Theranostics 2012, 2(5) 
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firming uptake in known tumor sites, but instead to 
derive dosimetry estimates for the therapeutic or to 
ensure that the product does not have an altered bio-
distribution. For these purposes, the agent needs to 
have similar biodistribution and clearance properties 
as  the  therapeutic.  This  requirement  often  compro-
mises its imaging quality and in turn optimal tumor 
detection.  
The Pretargeting Alternative 
 Early  development  of  bsMAb  pretargeting. 
Pretargeting was first suggested by investigators who 
were developing chelates for radiochemistry. It was 
well known that, unlike radiolabeled antibodies that 
were slowly cleared from  the body, chelated radio-
metals  were  quickly  and  efficiently  eliminated  [32]. 
Chelates  are  more  easily  radiolabeled  than  an  anti-
body and often yield higher specific activities.  
  While most researchers were coupling chelates 
to antibodies for direct radiolabeling, this group had 
developed  antibodies  to  EDTA  derivatives  and  de-
signed a new targeting agent, a bsMAb that bound 
both  the  tumor  and  separately  to  the  radiolabeled 
chelate. The bsMAb was not to be radiolabeled, but 
instead would be injected and given time to pretarget 
to the tumor. Once in the tumor and cleared from the 
blood and tissues, the radiolabeled chelate would be 
injected,  with  the  understanding  that  its  small  size 
would allow it to escape the vascular system quickly 
and then clear rapidly from all sites in the body, but 
when passing into the tumor, it would be captured by 
the pre-localized bsMAb. By separating the targeting 
of a slow clearing antibody from the fast clearing ra-
dionuclide,  the  procedure  aimed  to  increase  tu-
mor/nontumor ratios and allow for more rapid im-
aging. Over time, the concept was refined, eventually 
leading  to  clinical  testing,  starting  with  an  111In- 
labeled  benzyl-EDTA  containing  cobalt-bleomycin 
(BLEDTA  IV),  and  later  with  a  hydroxyethyl-
thiourido-derivative of benzyl EDTA that gave better 
tumor uptake in animal testing, 111In-labeled EOTUBE 
[33-35]. The clinical procedure settled on the admin-
istration  of  20  to  40  mg  of  a  bsMAb,  which  was  a 
chemically  conjugated  F(ab’)2  composed  of  an  an-
ti-carcinoembryonic antigen (CEA) Fab’ coupled to an 
anti-EOTUBE  Fab’.  Four  days  later,  the  patient  re-
ceived  111In-EOTUBE.  This  clinical  investigation  re-
ported a detection sensitivity of 95% for known tumor 
lesions, some detected within 4 h of the 111In-EOTUBE 
injection, including hepatic metastases, a site where 
other  clinical  studies  using  an  intact  111In-anti-CEA 
IgG  frequently  had  difficulty  because  of  the  high 
background activity in the liver [36, 37]. 
 It is perhaps not coincidental that CEA has been 
one  of  the  most  widely  studied  tumor  antigens  for 
pretargeting. Besides the fact that CEA targeting by 
directly radiolabeled antibodies was well established 
for  many  years,  such  as  in  the  first  preclinical  and 
clinical studies of radioimmunodetection [3, 4], anti-
bodies bound to CEA do not internalize readily. Since 
all  pretargeting  procedures  have  some  lag  time  be-
tween the injection of the primary targeting agent and 
the radiolabeled effector, it is important for the anti-
body to remain accessible until the effector is given. In 
addition  to  CEA,  we  have  examined  several  other 
pretargeting  systems  using  antibodies  that  are  not 
readily internalized: one against a colonic mucin (an-
tibody Mu-9 [38]), another against a pancreatic mucin 
(based on the humanized antibody hPAM4 [39, 40]), 
and a third against CD20 found on many B-cell lym-
phomas  (based  on  the  humanized  antibody  vel-
tuzumab [41, 42]). More recently, we have reported 
pretargeting results with a new tri-Fab bsMAb (TF12) 
[43] that is based on the humanized antibody desig-
nated  hRS7,  which  binds  to  Trop-2  (trophoblast-2; 
also known as EGP-1 or epithelial glycoprotein-1), an 
antigen found in increased expression by many dif-
ferent  types  of  epithelial  cancers  [44].  Successful 
pretargeting  with  the  TF12  bsMAb  was  surprising, 
since early studies had reported rapid internalization 
of the murine RS7 IgG [45-47]. Recently we found that 
while ~10 to 20% of the antibody is rapidly internal-
ized over 1-2 h, the remaining antibody remains ac-
cessible on the surface of the cell, with ~40-50% of the 
antibody internalized over 24 h (unpublished results). 
Thus, there was sufficient bsMAb remaining on the 
surface for highly successful pretargeting of a variety 
of human tumor xenografts, including prostate and 
ovarian cancers [43]. Other antibodies, such as against 
CD22,  that  are  more  readily  and  more  completely 
internalized, do  not  make good pretargeting agents 
[48]. However, the TF12 anti-Trop-2 experience illus-
trates  the  importance  of  carefully  reviewing  how 
much  antibody  is  retained  on  the  surface  of  tumor 
cells  before  dismissing  an  antibody  as  a  useful 
pretargeting agent.  
 Although  the  initial  pretargeting  concept  was 
based  on  a  bispecific  antibody,  other  dual-binding 
systems have been employed successfully. Hnatowich 
et al. [49] described systems using avidin-biotin, and 
later, this group developed another pretargeting sys-
tem  based  on  oligomer  binding  by  complementary 
oligomers [50-54]. The avidin-biotin pretargeting ap-
proach eventually split into 2 basic procedures, one 
using  a  streptavidin-IgG  conjugate,  which  later 
evolved to using a molecularly-engineered multiva-
lent scFv-streptavidin-fusion protein for binding ra-
diolabeled biotin, and another that pursued a pretar-Theranostics 2012, 2(5) 
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geted  biotinylated  IgG  conjugate  that  bound  radio-
labeled  biotin  after  being  bridged  by  streptavidin. 
These  other  pretargeting  procedures  have  been  re-
viewed previously [55-57] and will not be discussed 
further.  While  each  of  these  other  procedures  has 
special merits, the avidin-biotin systems have to con-
tend with the immunogenicity of avidin/streptavidin, 
since these are foreign proteins [58]. Hence, we have 
favored  the  bsMAb  approach  because  the  primary 
targeting agent can be humanized to reduce its im-
munogenicity.  
 Despite having encouraging clinical results with 
the  first  bsMAb  pretargeting  system,  this  was  not 
pursued, perhaps in part because clinical studies with 
123I-  and  99mTc-labeled  fragments  of  anti-CEA  anti-
bodies being developed at the same time were suc-
cessful, with tumor localization possible within a few 
hours and an excellent ability to disclose hepatic me-
tastases [59-64]. The lower cost and ease of prepara-
tion  of  99mTc-Fab’  displaced  future  development  of 
123I-labeled fragments. Ultimately 4 radiolabeled an-
tibodies received FDA approval for imaging, but over 
time, all but one of these [Indium (111In) capromab 
pendetide;  EUSA,  Langhorne,  PA)  have  been  with-
drawn,  because  18F-fluor-deoxyglucose  (18F-FDG) 
used  with  positron-emission  tomography  (PET)  im-
aging  systems  provided  better  sensitivity  at  lower 
expense than the radiolabeled antibodies, and could 
also  have  high  specificity  when  used  with  hybrid 
PET/CT cameras.  
 Instead of competing with directly-radiolabeled 
antibodies  for  imaging,  all  pretargeting  procedures 
focused on their therapeutic prospects. With bsMAb 
pretargeting, investigators in France discovered they 
could enhance the binding of a hapten (e.g., DTPA 
loaded  with  indium)  to  a  tumor  pretargeted  by  a 
bsMAb  by  attaching  2  haptens  to  a  short  peptide 
composed  of  2  amino  acids,  tyrosine  and  lysine 
[TL-(In)DTPA].  This  localized-binding  enhancement 
was termed the “affinity enhancement system” (AES) 
[65]. Others later confirmed that a structure contain-
ing 2 haptens improved uptake and retention in the 
tumor [66, 67]. With the TL-(In)DTPA hapten-peptide, 
tyrosine  could  be  radiolabeled  with  131I  for  therapy 
and imaging, while the DTPA haptens could chelate 
111In. D-amino acids were used to reduce the risk of 
enzymatic cleavage [68]. Initial clinical studies exam-
ined the  111In-labeled agent to define the best condi-
tions  for  pretargeting  in  patients,  again  using  a 
chemically-conjugated  Fab’  x  Fab’  bsMAb  targeting 
CEA, with the anti-hapten binding arm being an an-
ti-(In)DTPA antibody [69, 70], while preclinical stud-
ies  were  focusing  on  the  development  of  the 
131I-labeled hapten-peptide [71-73].  
Innovations in anti-hapten/hapten binding sys-
tems.  One  of  the  limitations  of  bsMAb-pretargeting 
system was the anti-hapten binding arm, which was 
commonly  directed  to  the  chelate  loaded  with  the 
radiometal  of  interest.  As  Reardon  et  al.  [32]  had 
shown with the anti-EDTA antibodies, binding affin-
ity changed, sometimes remarkably, based on which 
metal  was  loaded  in  the  chelate.  The  734  an-
ti-(In)DTPA antibody used by the French investiga-
tors had an affinity of 10-9 M for (In)DTPA, but with 
(Ca)DTPA, the affinity dropped to 10-3 M [74]. Thus, 
that antibody was so specific for the indium-loaded 
DTPA  that  it  would  not  bind  as  strongly  to  DTPA 
loaded  with  other  metals.  Additionally,  the  DTPA 
derivative used as the initial immunogen did not bind 
as avidly as other radionuclides of therapeutic inter-
est, such as  90Y, which would lead to high bone up-
take. Thus, while 131I is very suitable for therapy, other 
radionuclides  would  be  of  interest  for  a  variety  of 
reasons. However, if a different radionuclide were to 
be  used,  it  appeared  that  a  new  antibody  directed 
against the specific anti-chelate-metal complex might 
be  required.  This  limitation  was  partially  circum-
vented by inserting a ligand-binding agent that would 
bind  99mTc  for  imaging  or  rhenium  (e.g.,  188Re)  for 
therapy. To do this, the peptide length was increased 
to 4 amino acids, placing the 2 DTPA moieties on the 
first and third amino acids, thereby keeping the spa-
tial proximity of the 2 haptens in a similar configura-
tion  as  the  TL-(In)DTPA  peptide,  and  inserting  the 
3-thiosemicarbazonyl)glyoxylcysteinyl  (Tscg-Cys) 
moiety  on  a  terminal  Lys  (fourth  amino  acid)  [75]. 
While this manipulation successfully allowed the use 
of  another  series  of  radionuclides,  this  particular 
pretargeting system could not be expanded easily to 
other radionuclides.  
 Le  Doussal  et  al.  [65]  first  mentioned  an  an-
ti-hapten  antibody,  679,  that  bound  to  hista-
mine-succinyl-glycine (HSG), and Janevik-Ivanovska 
et al. [76] then examined this antibody-hapten system 
more thoroughly, reporting various di-HSG peptide 
derivatives used with 131I. The 679 antibody was pre-
pared  originally  as  part  of  an  effort  to  develop  an 
immunoassay to detect histamine, binding HSG with 
nanomolar affinity, but not to histamine. Since HSG 
was not involved in binding the radionuclide, pep-
tides could be crafted that maintained 2 HSG moieties 
with an appropriate spacing for AES, but other com-
pounds suitable for binding any radionuclide of in-
terest could be added (Figure 1).  Theranostics 2012, 2(5) 
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Figure 1. The HSG-hapten binding system for binding a variety of radionuclides. (A) The initial bsMAb pretargeting systems 
utilized antibodies that bound to a specific chelate-metal complex, e.g., indium-loaded DTPA. As such, the anti-(In)DTPA antibody had a 
much lower binding affinity for DTPA loaded with another metal, such as 90Y. Thus, to bind another radiometal, like 90Y, a new anti-chelate 
antibody would need to be prepared. An antibody against a hapten that does not bind the radionuclide, such as the anti-HSG (hista-
mine-succinyl-glycine) antibody, would open the possibility for using different radionuclides or other compounds with one system. (B) In 
the HSG-binding system, a peptide core of D-amino acids (aa) has 2 HSG haptens to enhance tumor-binding stability. The remaining 
structure can be modified to accommodate any radionuclide-binding agent. A tyrosine in the peptide core could be radioiodinated. We 
have also modified the carboxyl end of the peptide to allow for binding of fluorescent dyes. (C) For pretargeting, the bsMAb is first 
localized in the tumor, and after clearing from the blood and tissues, the radiolabeled divalent hapten-peptide is given. The divalent hapten 
structure enhances its binding avidity to the bsMAb, and it can potentially enhance the binding avidity of the bsMAb to the tumor as well. 
Trivalent bsMAbs with divalent binding to the tumor are preferred.  
 
 
We showed the potential universality of this an-
ti-hapten  binding  system  for  pretargeting  using  3 
different  peptides,  one  having  the  Tscg-Cys  moiety 
for binding 99mTc or 188Re, another with a single DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid)  moiety,  which  was  capable  of  binding  111In, 
177Lu,  and  90Y,  and  a  third  having  a  DOTA  and 
Tscg-Cys moiety [38]. When radiolabeled with 99mTc, 
the  hapten-peptide  bearing  Tscg-Cys  and  DOTA, 
designated IMP245, had significantly lower uptake in 
the tissues, such as liver and kidneys, than the hap-
ten-peptide with just the Tscg-Cys moiety. This find-
ing illustrates another important aspect of the pretar-
geting  methodology;  namely,  the  hapten-peptide 
structure can be modified in various ways to alter its 
biodistribution and clearance. As long as the structure Theranostics 2012, 2(5) 
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contains  2  haptens,  it  will  have  higher  uptake  and 
retention in tumors than a peptide bearing a single 
hapten.  We  typically  strive  to  ensure  the  hap-
ten-peptide structure encourages renal over hepato-
biliary elimination, with minimal renal retention, but 
the structure could be modified to encourage hepatic 
uptake  if  an  indication  required  less  background 
around  the  kidneys  or  urinary  bladder.  The  tu-
mor/kidney ratios for the various radiometal-labeled 
hapten-peptide structures that we have investigated 
have  been  ≥2:1,  usually  within  1  h,  whereas  tu-
mor/kidney  ratios  for  renally-filtered,  direct-
ly-radiolabeled,  antibody  fragments/constructs  can 
achieve this only when radioiodinated. In addition to 
harboring  a  single  DOTA  moiety,  the  di-HSG  hap-
ten-peptide IMP288 also contains a tyrosine, and has 
been radiolabeled successfully with124I in addition to 
90Y,  177Lu,  111In, and  68Ga [77-80]. For clinical devel-
opment,  we  showed  the  di-HSG  hapten-peptide, 
IMP288, did not bind to or block the binding of his-
tamine to H1, H2, H3, or H4; it could be given safely 
to guinea pigs (highly sensitive to histamine) in molar 
concentrations  more  than  1000-fold  higher  than  re-
quired for human dosing with 90Y, and the anti-HSG 
antibody  showed  no  binding  to  human  tissues  by 
immunohistology [81]. Thus, the anti-HSG/HSG sys-
tem was compatible for human use and it offered the 
possibility for pretargeting virtually any radionuclide 
that could be bound stably to a chelate or chelate-like 
structure. 
Innovation  in  bsMAb  structure.  The  first 
bsMAbs were prepared chemically by combining Fab’ 
fragments from each of the IgG antibodies of interest 
(Figure 2). The resulting F(ab’)2 conjugate was smaller 
in size than an IgG lacking the Fc, so it was cleared 
effectively from the blood over several days. Animal 
studies  with  chemical  conjugates  using  IgG,  F(ab’)2 
and Fab’ fragments revealed divalent binding to the 
tumor antigen yields higher and longer retention in 
the tumor [82], and thus we focused on developing 
humanized  bispecific  constructs  that  have  divalent 
binding to tumor [83-85].   
Clinical investigations have begun with a bsMAb 
prepared  using  the  Dock-and-Lock  (DNL)  method 
(Figure 2). This procedure combines 3 Fabs, 2 directed 
against the tumor antigen and one against the hapten 
(HSG)  in  a  unique  manner,  utilizing  the  natural 
binding  interaction  of  peptides  derived  from  two 
human proteins [85]. The dimerization and docking 
domain (or DDD) peptide consists of a 44 amino acid 
sequence derived from the regulatory subunit of hu-
man type II A-kinase. It forms a stable homodimer, 
which also acts as a docking site for the second pep-
tide, the anchor domain (or AD), which consists of a 
17-amino acid sequence derived from an interactive 
human A-kinase anchor protein. Once docked, the 3 
Fabs have a specific orientation allowing them to each 
bind  at  their  native  affinity.  These  peptides  were 
modified by inserting cysteines in strategic locations 
so that they will interact when the DDD and AD are 
docked together, thereby strengthening their binding 
by forming covalent disulfide bonds. Animal and pa-
tient studies found that these constructs are stable in 
serum [81]. This novel technology has allowed easy 
production of a number of different tri-Fab bsMAb, as 
well as many other multivalent, mono- or bispecific 
structures [57, 86, 87].  
Principles of bsMAb pretargeting. AES dictates 
that the divalent hapten structure encourages reten-
tion  in  the  tumor,  where  the  concentration  of  the 
bsMAb is higher than in the blood or in the tissues. 
This enhancement occurs because the binding avidity 
of a divalent hapten is better than the affinity derived 
by  a  monovalent  form.  However,  conceptually,  the 
divalent  hapten-peptide  could  cross-link  2  adjacent 
Fab’ x Fab’ bsMAbs, which would enhance the bind-
ing  of  the  bsMAb  to  the  tumor,  particularly  if  the 
bsMAbs were themselves only monovalently-bound 
to the tumor. Hapten binding could thus cross-link 2 
bsMAbs, stabilizing not only its hold on the bsMAb, 
but also the bsMAb binding to the tumor. An oligo-
mer-pretargeting system is also enhanced by divalent 
binding  [88,  89],  whereas  avidin-biotin  approaches 
rely  on  their  ultra-high  affinity  (10-15  M)  for  stable 
binding. However, with all of these approaches, the 
radiolabeled compound will be retained in the tumor 
only as long as  the antibody remains bound to the 
antigen expressed on the tumor cell. 
The principles of AES often focus on the divalent 
hapten for enhanced retention in the tumor, but the 
principle  also  relates  to  how  the  bsMAb  and  hap-
ten-peptide interact in the serum. As long as the con-
centration of the bsMAb is low in the serum when the 
divalent hapten-peptide is given, it would most likely 
bind a single bsMAb. This monovalent binding allows 
the hapten-peptide to release readily in the serum and 
continue  to  be  cleared  rapidly,  while  in  the  tumor, 
where presumably the bsMAb concentration is high-
er,  the  divalent  hapten-peptide  will  be  held  more 
tightly. The bsMAb concentration required for favor-
able release in the serum will vary based on the affin-
ity  of  the  anti-hapten  antibody.  With  the  an-
ti-HSG/HSG system, we found that that as long as the 
concentration of the bsMAb in the blood was ≥10-fold 
lower  than  the  concentration  of  the  hapten-peptide 
the  instant  it  was  injected  (assuming  instantaneous 
distribution in the vascular volume), >95% would be 
cleared within 1 h [81]. Theranostics 2012, 2(5) 
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Figure 2. Bispecific antibody conjugates/constructs. Chemically conjugated bsMAb were prepared from Fab’ fragments of the 
anti-tumor  (α-T)  and  the  anti-hapten  (α-H)  antibodies.  The  anti-tumor  Fab’  was  coupled  first  to  the  bifunctional 
N,N”-o-phenylene-dimaleimide (PDM), and then the anti-hapten Fab’ was added to form a stable Fab’ x Fab’ bsMAb. Molecularly engi-
neered bsMAb used by our group include the hBS14 (anti-CEACAM5 x anti-679 HSG) and several tri-Fab (TF) constructs, each binding to 
a different tumor antigen, but all using the anti-HSG hapten-binding antibody. Whereas the hBS14 construct is prepared in a single 
antibody-producing clone, the tri-Fab Dock-and-Lock constructs are formed from 2 separate clones. One produces the anti-tumor fusion 
protein, using the docking and dimerization domain (DDD) peptide sequence that has a strategically placed cysteine (designated DDD2). 
The Fab-DDD2 forms a dimer, which has a docking domain that will bind to the anchoring domain sequence, which is also modified to 
include 2 cysteines (AD2). Thus, all these constructs have bivalent binding to the tumor and monovalent binding to the hapten.  
 
 
As  the  concentration  of  the  bsMAb  increases 
relative  to  the  hapten-peptide,  the  hapten-peptide’s 
clearance  slows,  but  it  still  clears  much  faster  than 
most directly-radiolabeled antibody fragments. If the 
bsMAb in the blood is too high, the fraction of hap-
ten-peptide available for effective tumor localization 
would  be  decreased  significantly,  resulting  in  low 
tumor uptake. It is tempting to assume that the for-
mation  of  bsMAb-hapten-peptide  complexes  in  the 
blood may be beneficial, with the prospect that these Theranostics 2012, 2(5) 
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complexes would still localize in the tumor, but the 
important tenet behind pretargeting is rapid uptake in 
the tumor and clearance from the blood; formation of 
a large complex in the blood does not encourage rapid 
clearance of radiolabeled hapten-peptide, and in vivo 
studies  have  shown  tumor  uptake  can  be  reduced 
significantly  if  the  amount  of  complexation  is  un-
checked  [81,  90].  Thus,  with  a  bsMAb  pretargeting 
system, reducing the interval between a fixed amount 
of  bsMAb  and  hapten-peptide  will  slow  the  blood 
clearance of the hapten-peptide. An acceptable clear-
ance  rate  for  the  radiolabeled  hapten-peptide  may 
need  to  be  determined  empirically.  Bispecific  anti-
body  pretargeting  using  a  chemically-conjugated 
F(ab’)2 found an interval of 4 days to be optimal with a 
40  mg/m2  bsMAb  dose  [91,  92].  Using  an  an-
ti-CEACAM5 x anti-HSG tri-Fab bsMAb (TF2), clini-
cal studies have found that changing the interval from 
5 days to 1 day in patients given 75 mg of the bsMAb 
had only modest effects on the hapten-peptide clear-
ance (5-day interval, 96% and 99.9% cleared within 6 
and 24 h; a 1-day interval had 83 and 98.9% cleared 
within 6 and 24 h) [93]. These results reflect the initial 
clinical  finding  that  most  of  the  TF2  bsMAb  had 
cleared  within  1  day  [81,  93].  Ongoing  studies  are 
continuing to assess the effects of varying bsMAb and 
hapten-peptide dose, and interval, on hapten-peptide 
clearance and tumor localization with this system. It 
should be mentioned that with avidin-biotin methods, 
the  ultra-high  affinity  makes  it  imperative  that  the 
primary targeting agent be cleared as thoroughly as 
possible, and therefore these methods have utilized a 
clearing step so the radiolabeled biotin can be given 1 
day after the primary targeting agent injection.  
 There  are  2  other  important  aspects  that  all 
pretargeting systems have in common. First, the dose 
of the primary targeting agent, in our case the bsMAb, 
has to be sufficient to optimize the capture of the ra-
diolabeled  hapten-peptide,  and  second,  the  dose  of 
the  hapten-peptide  should  be  low,  and  therefore  it 
should be radiolabeled at a high specific activity. We 
optimized  the  labeling  of  the  di-HSG-DOTA  hap-
ten-peptide,  IMP288,  to  a  specific  activity  of  ~2.8 
mCi/nmole.  At  this  level,  radiolabeling  yields  are 
>97%, and therefore purification is not required (ex-
cess DTPA is added at the end of the labeling proce-
dure to ensure no free 90Y is present). Higher specific 
activities  are  possible,  but  then  purification  also 
would be required.  
 Although the tri-Fab constructs have the same 
molecular size and divalent tumor-binding properties 
as an IgG, because they clear quickly from the blood, 
the percent uptake in the tumor is lower than a di-
rectly-radiolabeled IgG. Estimates based on radioio-
dinated  tri-Fab  given  to  tumor-bearing  mice  have 
found  maximum  accretion  occurs  within  ~6  h,  but 
blood concentrations are too high at this time for the 
hapten-peptide  to  be  given  with  optimal  targeting 
results. Thus, the hapten-peptide injection is delayed 
in animals for 16-24 h, and at this time, ~2 to 4% of the 
tri-Fab’ is in the tumor.  
Various models have indicated that it is best to 
administer enough of the pretargeting agent to nearly 
saturate  antigen  [94-96].  This  is  logical,  since  the 
pretargeted agent is acting as a binding site for the 
radiolabeled compound. However, while this might 
be  true  in  theory,  and  perhaps  even  in  xenograft 
models, this is just not practical clinically, where tu-
mor  burden  and  antigen  content  (and  accessibility) 
are highly variable. One could elect to give exceeding 
high  loading  doses,  but  this  would  likely  require  a 
clearing agent to lower concentrations of the primary 
targeting agent in the blood to reasonable levels in a 
reasonable amount of time. We take a somewhat dif-
ferent view, suggesting that the optimal bsMAb dose 
does not have to be adjusted based on antigen content 
in the tumor, but rather on the amount of the hap-
ten-peptide  that  will  be  given,  with  the  hap-
ten-peptide  dose  dependent  on  its  specific  activity 
and the maximum tolerated dose (MTD), if using a 
therapeutic. In our system, tumor uptake of the radi-
olabeled hapten-peptide is reasonably high when 10- 
to 20-fold more moles of the bsMAb are injected as 
compared  to  the  moles  of  hapten-peptide  dose 
planned to be given [90, 97]. While in xenograft mod-
els there may be incremental improvements in tumor 
uptake as the bsMAb dose is increased beyond this 
amount, increasing the bsMAb dose also introduces 
more moles of bsMAb in the serum, which can impact 
the interval used. While extending the  interval  will 
reduce bsMAb concentrations in the serum, supplies 
in the tumor may diminish as well, which could re-
duce  the  amount  of  hapten-peptide  that  could  be 
captured [91]. Following the lead of how pretargeting 
is optimized in animals will provide a good starting 
point for clinical investigations, but because there are 
many factors that are beyond our control clinically, 
optimization often becomes a compromise to achieve 
a  reasonably  high  tumor  uptake  and  tu-
mor/nontumor ratios.  
While it may not be necessary to inject enough of 
the primary targeting agent to saturate the antigen in 
the tumor, other studies have shown there is a critical 
mass  of  bsMAb  required  for  optimal  uptake  of  the 
radiolabeled hapten-peptide (i.e., an appropriate dose 
of  bsMAb  is  not  governed  only  by  the 
bsMAb/peptide  molar  ratio).  For  example,  while  a 
10:1 bsMAb/hapten-peptide ratio gave excellent tar-Theranostics 2012, 2(5) 
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geting results at a given amount of bsMAb and hap-
ten-peptide,  if  the  concentration  of  each  agent  was 
reduced,  yet  this  proportionality  kept  the  same, 
eventually  a  level  would  be  reached  where  the 
amount of bsMAb in the tumor was too small to offer 
a reasonable capture of the hapten-peptide [97]. These 
preclinical results suggest that in situations where the 
specific activity of the hapten-peptide is very high, it 
may  be  necessary  to  maintain  a  minimum  bsMAb 
dose to encourage optimal tumor uptake with high 
tumor/nontumor  ratios.  Early  clinical  studies  with 
the anti-CEA x anti-(In)DTPA Fab’ x Fab’ bsMAb had 
indicated  that  the  minimum  bsMAb  for  acceptable 
tumor  uptake  should  be  0.1  mg/kg  using  0.1 
nmole/kg  of  the  hapten-peptide  [69,  70].  While 
pretargeting procedures do require more adjustments 
than direct methods, preclinical studies provide con-
siderable insights that help narrow the choices that 
will lead to excellent pretargeting results.  
Theranostics: Imaging Enhancement 
Pretargeting was first conceived as a procedure 
to improve imaging by reducing background activity, 
thereby enhancing tumor/nontumor ratios. Thus, it is 
not surprising that in preclinical testing, pretargeting 
has  provided  an  exceptional  ability  to  detect  small 
lesions in xenograft models.  
Initial  testing  of  our  pretargeting  systems  fo-
cused on the utility of a 99mTc-labeled hapten-peptide 
pretargeted  with  a  humanized  recombinant  an-
ti-CEACAM5  x  anti-HSG  bsMAb  for  detecting  sub-
cutaneous xenografts of a human colonic cancer cell 
line,  GW-39  [97].  Arcitumomab  (CEAScan®,  Im-
munomedics, Inc., Morris Plains, NJ), a 99mTc-Fab’ that 
also binds CEACAM5 and was approved by the FDA 
and EMA for detecting colonic cancer metastases was 
the  primary  comparator  [98-100].  Dynamic  imaging 
revealed  uptake  of  a  99mTc-hapten-peptide  could  be 
appreciated within 10 min of its injection in the ani-
mals given the bsMAb, although there was still simi-
lar concentrations in the heart and liver, and some-
what  higher  uptake  in  the  kidneys  (Figure  3)  [97]. 
Over the next 10 min, cardiac, hepatic, and renal up-
take decreased and tumor uptake intensified, yielding 
clear images of the tumor within 20 to 40 min. In con-
trast, over this same period, the  99mTc-Fab’ was seen 
only  in  the  blood  pool  and  kidneys.  Although  the 
dynamic imaging study used animals with large tu-
mors, subcutaneously-implanted tumors as small as 
0.1 g were easily discerned with pretargeting within 1 
h [97]. Even after 24 h, pretargeting continued to be 
superior to the 99mTc-Fab’ fragment.  
The rapidity and high sensitivity of pretargeting 
with  the  99mTc-hapten-peptide  suggested  that  this 
procedure  could  compete  favorably  with 
18F-fluordeoxyglucose (18F-FDG), the most commonly 
used imaging agent in oncology. In order to compare 
the 2 procedures, we needed a hapten-peptide labeled 
with  a  PET-imaging  radionuclide.  One  of  the  hap-
ten-peptides  being  used  for  90Y-labeling  also  had  a 
tyrosine as one of the amino acids in its peptide core, 
and with the commercial availability of 124I for human 
use,  a  procedure  was  developed  to  radioiodinate  it 
with 124I [77]. Animals bearing subcutaneous LS-174T 
human colonic cancer xenografts were pre-localized 
with the anti-CEACAM5 bsMAb and 1 day later given 
the  124I-hapten-peptide.  Another  group  was  fasted 
overnight and then given 18F-FDG, and a third group 
was  injected  with  124I-labeled  Fab’  of  the  same  an-
ti-CEACAM5 antibody used in the bsMAb. This was 
an  important  control,  because  directly-radiolabeled 
antibody fragments are often reported to have the best 
imaging properties when radioiodinated. This study 
found  pretargeting  provided  less  ambiguous  locali-
zation of the tumor. Images of animal taken ~1.5 h 
after each injection showed similar uptake with the 
pretargeted  124I-hapten-peptide  as  18F-FDG,  but  the 
pretargeted image had lower tissue uptake (Figure 4). 
The bone marrow of mice had exceptionally high up-
take of 18F-FDG, along with the expected uptake in the 
heart wall and brain, and diffuse uptake in the ab-
domen. As  in the earlier  study  with  99mTc-Fab’, the 
124I-Fab’  was  unable  to  demonstrate  tumor  localiza-
tion  over  the  first  few  hours,  and  there  was  much 
higher renal uptake and evidence of higher dehalo-
genation, with strong uptake in the stomach and later 
in  the  thyroid.  While  tumor/nontumor  ratios  im-
proved for the 124I-Fab’ by 24 h, with clear tumor lo-
calization, tumor uptake for the pretargeting proce-
dure  was  nearly  15-fold  higher.  This  was  the  first 
demonstration that pretargeting could improve image 
quality  over  18F-FDG,  while  also  showing  it  could 
provide much improved images than a directly radi-
oiodinated Fab’ fragment.  
In  order  to  provide  a  greater  challenge  for 
pretargeting,  the  GW-39  human  colonic  tumor  cell 
line was injected intravenously, allowing it to develop 
as small metastatic colonies scattered within the lungs 
[101]. These animals were pretargeted using a tri-Fab 
anti-CEACAM5  bsMAb  and  one  day  later  received 
the  124I-hapten-peptide,  while  a  separate  group  of 
animals was given  18F-FDG (Figure 5) [79]. PET im-
aging showed a remarkable ability of the pretargeting 
procedure to detect uptake in the lungs, while there 
was no indication of tumor in the lungs of animals 
given  18F-FDG,  even  though  biodistribution  studies 
showed GW-39 was equally avid for FDG as LS-174T. 
Indeed,  transverse  sections  of  the  chest  in  animals Theranostics 2012, 2(5) 
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given the pretargeting procedure appeared to show 
discrete uptake in small nodules, but no evidence of 
targeting  was  seen  with  18F-FDG.  After  completing 
the  imaging  study,  a  histological  evaluation  of  the 
lungs revealed multiple nodules scattered throughout 
the lungs, with no single nodule exceeding 0.3 mm in 
diameter (Figure 5). Autoradiography studies in this 
same  model  using  an  111In-labeled  hapten-peptide 
showed  that  localization  of  the  hapten-peptide  was 
restricted to uptake around the tumor nodules, but 
not in the normal lung. Collectively, these data estab-
lished the superior sensitivity afforded by the pretar-
geting procedure over 18F-FDG, disclosing pulmonary 
metastases that were smaller than metastases detected 
to-date by any other imaging procedure in such xen-
ograft models. Further studies in a mouse model that 
bore a human tumor xenograft in one leg and a focal 
inflammation in the opposite one again confirmed the 
improved  specificity  of  pretargeting  over  18F-FDG, 
when the focal inflammation was not detected in the 
pretargeted  animal,  but  did  localize  with  18F-FDG 
[102]. Thus, pretargeting has superior sensitivity and 
specificity  over  18F-FDG  in  small  animal  imaging 
studies. 
 
Figure 3. Pretargeted 99mTc-hapten-peptide vs. 99mTc-Fab’. Nude mice bearing large (1.3 to 1.5 g) human colonic tumor xeno-
grafts (arrows in photos) were used to assess the dynamics of a 99mTc-hapten-peptide alone or pretargeted with an anti-CEA bsMAb given 
48 h earlier, and compared to an 99mTc-anti-CEA Fab’ fragment. Dynamic imaging was performed over 60 min, taking images at 2-min 
intervals. Static images of these same animals were then also taken at 1, 6, and 24 h. Panel A shows the dynamic images taken from 10 to 
20 minutes that illustrate the pretargeted 99mTc-hapten-peptide with uptake in the tumor (T) as early as 10 min after its injection, but at 
this time, tumor uptake was similar to the heart (H), with more intense uptake in the kidneys (K) and liver (Lv). Substantial activity had 
already been eliminated in the urinary bladder (UB). Over the next 10 minutes, uptake in heart and liver diminished so that they were not 
visible, and the tumor’s intensity was now similar to the kidneys. In Panel B, the 2-min dynamic ending at 40 min showed tumor uptake 
had exceeded the kidneys. The static images shown in Panel C illustrate the targeting seen with the 99mTc-anti-CEA Fab’ fragment (top), 
the 99mTc-hapten peptide alone (no bsMAb was given; middle), and the pretargeted 99mTc-hapten-peptide (bottom). The 99mTc-anti-CEA 
Fab’ showed only a minor blush in the tumor at 1 h, with most of the activity residing in the blood, liver and kidneys, with some elimination 
in  the  urinary  bladder.  The  follow-up  images  show  tumor  localization,  but  renal  uptake  is  much  more  prevalent.  Even  the 
99mTc-hapten-peptide alone showed some uptake in the tumor over the first 6 h, but by 24 h, all activity was eliminated from the body. In 
contrast, the animal pretargeted with the anti-CEA bsMAb show strong tumor localization that persisted over time as the normal tissues 
continued to wash out.  Theranostics 2012, 2(5) 
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Figure 4. PET imaging of nude mice bearing a s.c. human colonic tumor (T). A (top panel) shows an animal given an an-
ti-CEACAM5 bsMAb pretargeted 124I-hapten-peptide, B (middle panel) an 124I-labeled anti-CEACAM5 Fab’, and C (bottom panel) was 
given 18F-FDG. The far left side of each panel shows a transverse section taken through a plane that includes the tumor, with white lines 
in the adjacent coronal sections indicating the approximate location of the plane. For A and B, another transverse section through the 
abdomen in the region of the kidneys (K) is also shown, whereas C shows a transverse section that thorough a plane that includes the 
heart and another lower plane below the heart. The coronal slices are on the posterior side of the animal in order to highlight the tumor 
that is in on left side of the image. All images are adjusted to the same intensity without background subtraction to give a better appre-
ciation of the relative uptake in the tissues. The animals were not pre-medicated to ameliorate radioiodine uptake in the thyroid (Thy) or 
stomach (St). 18F-FDG has extensive uptake in the bone marrow (BM) of mice, as well as in the brain (Br) and heart wall (H).  Theranostics 2012, 2(5) 
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Figure 5. Localization of micrometastatic tumors the lungs of nude mice injected intravenously with a human colon cancer cell line. Nude 
mice were given a specific anti-CEACAM5 trivalent bsMAb or a control, non-binding trivalent bsMAb (anti-CD22 x anti-HSG). They then 
later received an 124I-hapten peptide. A separate group of animals received 18F-FDG. Images A and B are sagittal sections of 2 separate mice 
and corresponding transverse slices through the chest taken ~1 h after the 124I-hapten-injection. The lungs (L) of both animals showed 
increased uptake, and the transverse sections appear to show distinct uptake in small clusters. The sections were cut in a plane to include 
one of the kidneys (K) to illustrate uptake in this organ, as well as some activity in the stomach (St) immediately above the kidney. The 
activity is cleared in the urine (urinary bladder, UB). C shows a coronal section of a tumor-bearing mouse given the control bsMAb that 
did not find tumor in the chest. D shows coronal slices of 2 animals given 18F-FDG and imaged ~1 h later. E shows sagittal slices of these 
same 2 animals, and F and G are transverse sections through 2 different regions of the chest (F is higher than G). Even in the transverse 
sections, there was no indication of tumor involvement in lungs these animals, but there was intense uptake in the brain (Br), bone marrow 
(BM; e.g., ribs, scapula, spine, pelvis, femurs) and heart wall (H). The histology sections show lungs taken from one of the 18F-FDG imaged 
animals (animal to the right in panel D) that had multiple foci of tumor scattered in several lobes. A portion of the section highlighted in 
the rectangle is magnified, showing even the largest lesion in the field was only ~0.25 mm in diameter. A separate autoradiography study 
using animals with more advanced disease that were pretargeted with an anti-CEACAM5 bsMAb followed by an 111In-hapten-peptide 
showed uptake was specifically targeted to the tumor nodules in the lungs. 
 
 Theranostics 2012, 2(5) 
 
http://www.thno.org 
535 
These  imaging  studies  were  initiated  with  124I 
primarily  because  of  the  limited  availability  of 
PET-imaging  radionuclides  suitable  for  clinical  use. 
124I is commonly used with directly- radiolabeled an-
tibodies because its ~4-day half-life allows for delayed 
imaging, but it is expensive and high-energy gamma 
emissions are problematic. 64Cu also has been used for 
small  antibody  fragments,  peptides,  and  even  for 
pretargeting, but it has limited availability and cost is 
a  concern  [103].  68Ge/68Ga  generators  are  becoming 
more widely available  [104, 105].  68Ga, which is es-
sentially carrier-free with a physical half-life is ~1 h, 
could  be  an  important  agent  for  PET  imaging  with 
compounds that give an acceptable image within 1-2 
h. The generators can be used for >6 months, which 
can  significantly  reduce  the  overall  cost  if  multiple 
doses are prepared over this time. We found a DOTA, 
di-HSG hapten-peptide can be prepared at very high 
specific activities (e.g., starting at 48 mCi/nmole) and 
provide excellent images with 68Ga [102].  
The preferred radionuclide for PET imaging re-
mains 18F, but 18F chemistry is challenging and often 
laborious.  McBride  et  al.  [106]  recently  described  a 
novel and unique method for binding 18F to peptides. 
Historically,  while  most  radiofluorination  methods 
have  relied  on  direct  binding  of  fluorine  to  carbon 
atoms, these authors took advantage of fluorine’s high 
binding  affinity  to  metals,  particularly  aluminum, 
where  they  were  able  to  capture  the  highly  stable 
aluminum-fluoride  complex  using  a  chelate.  These 
efforts  identified  a  NOTA  structure  with  favorable 
binding properties to hold Al18F complexes stably in 
serum and in vivo. The initial compound inserted into 
the  hapten-peptide,  IMP449,  had  a  radiolabeling  of 
5-20% with a specific activity of 0.5 to 1.3 mCi/nmol, 
but  subsequent  refinements  in  the  chelate  structure 
and labeling conditions have raised the radiolabeling 
yields  to  ≥80%,  with  specific  activities  as  high  as  4 
mCi/nmol [107, 108]. The fluorination method is not 
applicable just for pretargeting peptides, but has been 
applied to other peptides as well [108-110]. The pro-
cedure  is  simple  and  quick,  and  while  the  general 
procedure will likely perform well with a number of 
peptides,  others  may  require  certain  adaptations  or 
purification  processes  to  optimize  yields  or  specific 
activities.  However,  the  process  for  18F-labeling  of 
pretargeting  peptides  has  been  reduced  to  a  single 
lyophilized vial that only requires the addition of 18F 
in saline, as used for bone imaging, and a brief car-
tridge purification procedure that can be completed 
within 20-30 min [110]. The method requires heating 
the chelate with the Al18F at high temperatures for 15 
minutes, which might not be suitable for all peptides, 
but McBride et al. [111] recently described an adapta-
tion of the procedure that allows even heat-sensitive 
compounds to be 18F-labeled easily and rapidly.  
Theranostics: Improving Therapeutic Out-
comes 
Pretargeting  procedures  easily  improved  the 
problematic  radiation  exposure  to  the  red  marrow 
that has been dose-limiting for directly-radiolabeled 
IgG  and  even  some  fragments.  However,  achieving 
therapeutic results also requires the targeting agent to 
deliver a high enough concentration to tumor for a 
sufficient duration to elicit a significant response. As 
mentioned earlier, compounds that clear quickly from 
the blood, such as a pretargeted peptide, likely have 
only one chance of achieving maximum accretion in 
the tumor, since the concentration in the blood is de-
pleted  so  quickly.  Indeed,  the  faster  a  direct-
ly-radiolabeled  antibody  clears  from  the  blood,  the 
more the concentration in the tumor usually decreas-
es. However, pretargeting appears to avoid this trend. 
Gautherot  et  al.  found  tumor  uptake  of  a  radioio-
dinated hapten-peptide pretargeted with an anti-CEA 
bsMAb could achieve similar tumor accretion as an 
131I-F(ab’)2 [71, 72]. They predicted and then showed a 
bsMAb  pretargeting  system  using  an  131I-labeled 
hapten-peptide would be a more effective therapeutic 
procedure  for  targeting  radionuclides  than  an 
131I-labeled IgG or F(ab’)2 [71-73, 112, 113]. However, 
an even more surprising result was a report by Ax-
worthy et al. [114], who found the uptake of radio-
labeled  biotin  in  a  tumor  pretargeted  with  a  strep-
tavidin-IgG conjugate could rival that of the direct-
ly-radiolabeled IgG, yet with much lower blood and 
tissue  concentrations.  This  group  later  published  a 
series of preclinical studies that showed a pretarget-
ing approach using 90Y-biotin could cure tumor xen-
ografts in mice more effectively than 90Y-labeled IgG 
[115].  All  of  these  studies  essentially  revealed  the 
therapeutic advantage for pretargeting is obtained by 
(a)  the  rapid  uptake  of  the  radiolabeled  compound 
(biotin  or  hapten-peptide)  that  reaches  a  maximum 
accretion within 1-2 h, as compared with an IgG that 
requires  1-3  days,  and  (b)  the  exceptionally  rapid 
elimination  of  radioactivity  from  the  blood,  signifi-
cantly  reducing  red  marrow  exposure  [57,  72,  115, 
116]. These 2 factors combine to increase the radiation 
dose  rate  in  the  tumor,  as  well  as  providing  better 
tumor/blood ratios.  
 In animal testing, we found that renal toxicity 
was dose-limiting for an optimized pretargeting pro-
cedure  [116].  Thus,  in  the  animals,  blood  clearance 
was sufficiently rapid to minimize marrow exposure, 
but because the vast majority of the activity was fil-
tered in the kidneys and eliminated in the urine, the Theranostics 2012, 2(5) 
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kidneys were the next organ of concern. Renal uptake 
in  mice  was  relatively  low,  with  a  first  generation 
hapten-peptide  having  a  maximum  uptake  of  just 
about 3% injected dose per gram (ID/g), while a se-
cond  generation  hapten-peptide  that  is  now  being 
used clinically was somewhat lower, being ~2% ID/g, 
with renal concentrations decreasing by about 20-40% 
per day [40]. Importantly, renal uptake of the radio-
labeled hapten-peptide was not affected over a wide 
range of pretargeting conditions [81, 90], and thus we 
expect that the radiation-absorbed dose to the kidneys 
in patients will be relatively constant as adjustments 
are  made.  Early  clinical  data  have  suggested  renal 
doses for the 90Y-hapten-peptide pretargeted with an 
anti-CEACAM5 bsMAb will be < 3 cGy/mCi [81]. In 
animals, tumor/kidney ratios easily exceed 2:1, which 
would  give  pretargeting  an  advantage  over  direct-
ly-radiolabeled antibody fragments that often have as 
much as 10-fold higher uptake in the kidneys than in 
tumor.  Therapy  studies  with  radiolabeled  peptides 
have  indicated  kidney  tolerance  up  to  ~2700  cGy 
based on conventional MIRDOSE [117, 118], and thus 
if similar ratios in animals can be achieved in patients, 
tumors could receive ≥ 5000 cGy at a maximum toler-
ated dose. Historically, dosimetry data for solid tu-
mors have shown a <2000 cGy delivery potential, with 
most  tumors  receiving  <1000  cGy  [119].  While  this 
radiation dose delivered to lymphomas is highly ef-
fective, meaningful anti-tumor responses in solid tu-
mors  have  been  rare.  However,  one  additional  ad-
vantage for pretargeting is the manner in which the 
radiation is delivered; namely, very quickly. As we 
and  others  have  emphasized  [57,  72,  115,  116], 
pretargeting could potentially deliver the same radia-
tion dose to tumor as a directly radiolabeled IgG, but 
because  the  hapten-peptide  reaches  its  maximum 
uptake within 1 h, the dose rate that the radiation is 
delivered  is  significantly  higher  than  with  an  IgG. 
This  is  expected  to  provide  an  added  boost  to  the 
therapeutic  potential  for  pretargeted  radionuclide 
therapy, but we also have to keep in mind that other 
tissues are also being exposed at higher dose rate, and 
even if it is for a short duration, the toxicity could also 
be affected.  
 Being  limited  by  renal  toxicity  has  its  draw-
backs, because the clinical manifestation of these ef-
fects often takes many months to appear and years to 
reach  full  effect.  Therefore,  Phase  I  dose  escalation 
trials will need to rely on imaging and dosimetry to 
guide patient treatment. While there have been some 
advances in renal dosimetry in an attempt to improve 
the correlation of exposure to toxicity by taking into 
account  the  biological  effective  dose,  there  is  still  a 
need for a more comprehensive data set before these 
estimates can fully account for long-term loss in renal 
function [120-125]. Interestingly, except for one trial 
where gastrointestinal toxicity was dose-limiting be-
cause of the specificity  of the primary anti-EpCAM 
conjugate, other pretargeting trials using 90Y-biotin or 
an 131I-hapten-peptide have been limited by hemato-
logic toxicity  [55, 56]. Such toxicities likely reflect a 
diminished  capacity  of  the  red  marrow  because  of 
prior treatments, but the radiation sensitivity thresh-
old of the red marrow is so much lower than the kid-
neys that even when radiation is cleared rapidly from 
the  blood,  severe  hematologic  toxicity  can  occur. 
Medullary thyroid cancer patients were found to have 
a lower tolerance to a pretargeted 131I-hapten-peptide, 
which  was  attributed  in  part  to  unappreciated 
bone/bone marrow metastases [92, 126]. Indeed, these 
investigators  found  pretargeting  could  enhance  the 
overall  survival  of  a  subpopulation  of  medullary 
thyroid  cancer  patients  who  had  a  short  calcitonin 
doubling time (serum biomarker for this indication), 
attributing this result to the successful elimination of 
these metastases [127].  
 By reducing the risk of myelotoxicity, the possi-
bility  of  combining  this  pretargeted  radionuclide 
therapy with other treatment modalities is more fea-
sible  than  with  a  directly-  radiolabeled  conjugate. 
Several  reports  have  shown  therapeutic  improve-
ments  in  animal  models  using  various  chemothera-
peutic, as well as other agents, combined with radi-
oimmunotherapy [40, 128-131]. There is even the pos-
sibility  that  pretargeted  radionuclides  can  be  com-
bined  with  improved  efficacy  with  antibody-drug 
conjugates, based on the fact that an antibody-SN-38 
conjugate (SN-38 is the active ingredient in irinotecan) 
could be combined with a maximum tolerated dose of 
a directly radiolabeled 90Y-IgG [132]. Moving forward, 
we also need to keep in mind, as studies in animals 
have  shown  [40],  that  fractionating  a  pretargeting 
procedure may be the best course of action.  
Summary 
Pretargeting  approaches  are  designed  to  have 
superior  targeting  properties  over  directly-targeted 
antibodies.  Unlike  directly-radiolabeled  antibodies, 
where a different form of antibody might be required 
for optimal imaging than used for therapy, in pretar-
geting, the conditions that favor imaging will likely be 
identical to those for therapy. Even if a different hap-
ten-peptide were necessary to allow a more favorable 
imaging  radionuclide  to  be  used,  such  as  a  posi-
tron-emitter, we often are able to modify the peptide 
structure in a manner that minimizes differences in 
biodistribution.  Preclinical  studies  have  already 
shown  pretargeting  can  be  more  specific  than  con-Theranostics 2012, 2(5) 
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ventional 18F-FDG, but specificity will be governed by 
the binding properties of the primary targeting anti-
body.  Our  initial  clinical  experience  with  an 
111In-labeled  hapten-peptide  used  primarily  for  do-
simetry  in  a  therapy  trial  encouragingly  has  found 
that  pretargeting  can  localize  18F-FDG-positive  le-
sions,  but  more  studies  aimed  at  optimizing  the 
pretargeting conditions are necessary. In addition, an 
18F-labeled hapten-peptide will soon be made availa-
ble  so  that  images  can  be  acquired  with  similar 
equipment.  
Pretargeting  procedures  do  require  more  ad-
vanced  investigations  to  determine  suitable  condi-
tions for delivering the radiolabeled compound, but 
preclinical  studies  can  provide  useful  insights  to 
guide which starting conditions and adjustments will 
likely  lead  to  the  best  localization  results  clinically. 
Pretargeting does require multiple injections, but the 
tri-Fab bsMAb pretargeting procedure has minimized 
this  process  to  2  injections,  with  clinical  data  sug-
gesting the spacing will likely range within 1-3 days. 
Because the radiolabeled compound clears so quickly 
from the blood and body, substantially more radio-
nuclide is required for pretargeted therapy than for 
direct targeting. Preclinical testing certainly indicates 
that improved anti-tumor responses with less toxicity 
occur in solid tumor and hematologic malignancies, 
possibly  justifying  these  additional  requirements. 
Clinical  studies  with  the  new  generation  tri-Fab 
bsMAb are assessing the prospects for this procedure. 
Fortunately, results to date confirm that pretargeted 
radioimmunodetection can be at least comparable to 
FDG-PET in terms of disclosing known sites of cancer. 
Whether the improved specificity noted and superi-
ority  to  FDG-PET  preclinically  can  be  confirmed  in 
patients must await clinical trials. 
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